Zacks Investment Research
27 Mar 2026, 23:15 UTC · 26w ago
Verdict
Headline leans bearish. We score PACB −0.40 across four claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−0.40moderately bearish
What the story claims
4 claims · scored −1 bearish … +1 bullish
Pacific Biosciences of California's upcoming quarterly EPS is projected at -$0.17, representing a 13.33% decrease year-over-year.
So whatA double-digit decline in earnings per share signals deteriorating profitability, which is fundamentally negative for the stock's valuation.
More negative than 95% of claims this week
Pacific Biosciences of California holds a Zacks Rank of #1 (Strong Buy) despite recent price declines and negative earnings revisions.
Continue reading
5 related stories
More negative than 70% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 87% of claims this week
Pacific Biosciences of California's stock fell 6.67% in the latest session and dropped 24.16% over the previous month.
More negative than 86% of claims this week
Pacific Biosciences of California's quarterly revenue is projected to be $41 million, indicating a 10.36% year-over-year increase.
More positive than 65% of claims this week
Which stocks this story touches
More negative than 70% of ticker scores this week
The stock is down significantly over the last month and earnings per share are projected to decrease.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
+28.6%
Price is moving against the score
$1.62 vs $1.26 close before publication (Mar 27) · not market-adjusted
PACB chart →